News

USA2 SPOTLIGHT 

USA2 SPOTLIGHT 

USA2 SPOTLIGHT 

MUST READS

A November 23, 2016 Reuters article reported that “Eli Lilly and Co said its experimental Alzheimer's treatment failed to slow loss of cognitive ability in patients with mild symptoms, a major setback for the company and millions of people at risk of developing the memory-robbing disease.”

MUST READS

Pages

^ Back to Top